TRITON and Beyond: New Insights into the Profile of Prasugrel
نویسندگان
چکیده
Prasugrel, a third-generation thienopyridine antiplatelet agent, demonstrated superior efficacy to clopidogrel but with an increased risk of bleeding in the phase III pivotal registration Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI 38). This article reviews and discusses select components of a large literature of prasugrel data that has emerged since the TRITON-TIMI 38 (TRITON) study primary disclosure.
منابع مشابه
The TRITON versus PLATO trials: differences beyond platelet inhibition.
Clopidogrel monopoly as an exclusive oral antiplatelet agent used in combination with aspirin or as a monotherapy for treatment or/and prevention of occlusive thrombotic vascular events has been recently challenged. Based on the indirect comparison of TRITON and PLATO trial data, ticagrelor is clearly superior to prasugrel in a population of patients with acute coronary syndrome (ACS) because o...
متن کاملPrasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger.
dogrel [1] . Patients with moderateto high-risk acute coronary syndromes with the defined coronary anatomy and planned stent placement were randomized to prasugrel or clopidogrel for 6–15 months. The primary endpoint was the time to the first event of cardiovascular death, myocardial infarction or stroke, and occurred in 12.1% of patients treated with clopidogrel and 9.9% of patients randomized...
متن کاملCritical review of prasugrel for formulary decision makers.
BACKGROUND Cardiovascular disease, including acute coronary syndromes (ACS) comprising ST-elevation and non-ST-elevation myocardial infarction (STEMI/NSTEMI) and unstable angina (UA), remains the leading cause of death in the United States. The direct and indirect costs of cardiovascular disease are estimated to surpass $165 billion in 2009. Antiplatelet pharmacotherapy has been shown to reduce...
متن کاملPharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
AIMS To examine the extent of platelet inhibition by prasugrel vs. clopidogrel in a TRITON-TIMI 38 substudy. METHODS AND RESULTS TRITON-TIMI 38 randomized acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) to prasugrel or standard dose clopidogrel. Selected sites prospectively enrolled TRITON-TIMI 38 patients to evaluate adenosine diphosphate (ADP)-atte...
متن کاملComparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention
Antiplatelet agents are the cornerstone of treatment for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Clopidogrel, when added to aspirin, has demonstrated considerable success at reducing thrombotic complications of ACS and/or PCI compared to aspirin alone and is standard of care for the management of patients with ACS and in patients undergoi...
متن کامل